Skip to content
Vivo logo
← All articles

Semax Nasal Spray: Evidence and Safety Review

Semax Nasal Spray: Evidence and Safety Review

Isometric illustration of evidence and uncertainty

Semax nasal spray has a small body of human research, almost all of it from Russia, and no established safety profile in the United States. FDA’s Pharmacy Compounding Advisory Committee (PCAC) reviewed it in 2026 and found insufficient evidence of effectiveness for the uses it examined, and it located no human pharmacokinetic studies, meaning no data on how the body absorbs and clears the peptide. This article separates human findings from animal and laboratory work, lays out what is known and unknown about safety, and explains how to read quality claims on products sold online.

VivoChoose Provider-Supervised Peptide CareVivo offers personalized treatment selection, medical supervision, and therapies prepared by licensed U.S. pharmacies and delivered to your door.Visit

TL;DR

  • Semax is a synthetic peptide developed in Russia and sold there as a prescription nasal drop. It is not an FDA-approved drug.
  • FDA’s PCAC review found insufficient evidence of effectiveness for cerebral ischemia, migraine and trigeminal neuralgia, and found no human pharmacokinetic studies by any route.
  • Human data are small Russian studies, mostly in stroke. Evidence for cognition in healthy adults is described as limited by independent academic summaries.
  • FDA found one adverse-event report and no published human case reports, which means safety is poorly characterized, not proven.
  • Products labeled “research use only” lack the documentation a prescription product would carry. A licensed provider and a licensed U.S. pharmacy are the baseline for any compounded therapy.

Table of Contents

What Semax is and what it has been studied for

Semax is a synthetic heptapeptide (a chain of seven amino acids) based on a fragment of ACTH, a natural hormone. According to FDA’s PCAC briefing, it was developed in Russia in the 1980s and is sold there as prescription nasal drops at 0.1% and 1% strengths. Russian labeling lists post-stroke recovery, vascular cognitive disorders, optic nerve disease and attention-deficit disorder in children.

The FDA review covered two forms, semax (free base) and semax acetate, for three proposed uses: cerebral ischemia (reduced blood flow to the brain), migraine and trigeminal neuralgia (a facial nerve pain condition). The proposed products were an intranasal spray or a subcutaneous injection at 7,500 µg/mL or 1,000 µg/mL.

Semax

Those are the uses with a regulatory record. Marketing pages often describe focus, memory or mood benefits, which are not what the reviewed literature primarily addresses.

What the human evidence shows

Human evidence means studies in people, as opposed to cells or animals. For Semax it is thin and regionally concentrated.

FDA’s PCAC document summarized the available human work:

  • A 2018 fMRI study of 24 healthy adults reported a difference in default-mode-network imaging (a pattern of resting brain activity) but no behavioral outcomes. An imaging change is not the same as a benefit someone can feel or measure in daily performance.
  • A 2018 meta-analysis of three stroke trials (181 participants) reported better stroke-scale and mobility scores than placebo in moderate and severe stroke.
  • A 110-patient stroke rehabilitation study reported higher BDNF (a protein linked to nerve growth) and better Barthel scores, a measure of daily-living ability.
  • A peptic ulcer trial reported healing in 89.5% versus 30.8% at day 14.

All of this is from the FDA PCAC document. Despite those results, the committee’s conclusion for cerebral ischemia, migraine and trigeminal neuralgia was that there was insufficient evidence to support effectiveness. It identified only two usable references for those uses, with small samples and insufficient design detail.

What independent reviewers say

An evidence summary from the Alzheimer’s Drug Discovery Foundation’s Cognitive Vitality program states that Semax is used in Russia as a neuroprotective drug for stroke. It adds that there is little evidence it improves cognition in healthy people, none for Alzheimer’s disease, and few published English-language human studies.

A July 2024 synthesis from the Compound Evidence Institute rated the evidence for Semax on cognitive performance and neuroprotection as very low certainty. It counted two contributing trials and downgraded for risk of bias and reporting limitations, not because no studies exist.

In practical terms, a reader who wants a nasal spray for focus or longevity is asking about a use the human literature has not tested well. The best-studied setting, stroke recovery, involves patients under hospital or specialist care, not self-directed use.

What animal and laboratory studies add

Much of the mechanistic story told about Semax, including effects on neurotrophic factors and brain chemistry, comes from cell and animal work. That work has real value, and it also has limits that matter when a product page implies human results.

The National Institutes of Health explains that animal models can be bred to be nearly genetically identical, fed on the same schedule and followed across a full lifespan. That control helps researchers isolate probable causes of disease. NIH also notes that moving from animal studies to an approved therapy can take decades.

The limits are equally documented. The U.S. EPA notes that doses producing effects in animals are often much higher than doses anticipated for humans, so results must be extrapolated across species and to lower doses, which adds uncertainty. Harvard’s Nutrition Source describes laboratory and animal studies as only a starting point, because animals and cells are not a substitute for humans.

One example from the FDA record shows why this matters for a nasal product. A 2006 rat study tracked radiolabeled Semax after intranasal dosing, and it is frequently cited online as proof of brain delivery. Rat tissue distribution does not establish how much reaches a person’s bloodstream or brain, and FDA found no human pharmacokinetic study for any route. Absorption, exposure and half-life in people remain open questions.

Safety: what is reported and what is not known

The safety record for Semax is short, and it is short because data are scarce.

  • Adverse-event reports. FDA’s adverse-event database (FAERS), searched through December 3, 2025, returned one report. A consumer who used Semax 0.1% nasal drops bought from an online seller developed eye pain and burning in May 2024, was hospitalized, and reported the pain had not resolved as of May 2025. The report does not prove cause, and FDA’s literature search also found no published human case reports of adverse events.
  • No pharmacokinetic data. Without them, no one can state a dose range tied to blood levels, a duration of action or an elimination time.
  • Interactions and long-term effects. The sources reviewed do not establish interactions with medications or the effects of prolonged use.
  • Product quality. For the free-base form, FDA noted that the nomination included no certificate of analysis, and that public information on impurity limits, microbial bioburden and endotoxin testing was lacking. Information on the proposed nasal-spray container-closure system was also unavailable.

The last point deserves attention. A nasal spray goes onto a mucous membrane near the eyes and brain, so sterility and endotoxin control (endotoxins are fragments of bacteria that can cause inflammatory reactions) are basic requirements, not extras.

People who are pregnant or breastfeeding, who have a history of stroke or a neurological or psychiatric condition, or who take regular prescription medication should discuss any peptide with their own physician before using it. A clinician can weigh a specific medical history in a way no article can.

Regulatory status and research-use products

The sources reviewed do not describe Semax as an FDA-approved drug. The PCAC evaluation exists because Semax was nominated for consideration under FDA’s compounding framework, and the committee’s finding on effectiveness was that evidence was insufficient. That is a review of a nomination, not a clearance.

That context explains the market you see in search results. Many pages sell Semax sprays labeled “research use only”, a label that signals the product is not intended for human use and is not made to a prescription standard. Others describe “doctor-formulated” or “GMP-made” blends without naming the prescriber or the pharmacy.

For anyone weighing a licensed route against research-chemical sourcing, three questions separate the two:

  1. Who prescribes? A licensed provider should review your history and be reachable for follow-up.
  2. Which pharmacy compounds it? The pharmacy should be a licensed U.S. facility, and you should be able to ask its name. Our guide to what patients should verify about a compounding pharmacy walks through that check.
  3. What documentation exists? Identity, purity and sterility testing should be on paper, not implied.

How to read a quality claim

FDA’s own list of what was missing for Semax doubles as a checklist for any peptide product.

  • Certificate of analysis (CoA). A document from a testing lab reporting identity and purity of a specific batch. Check that the batch number matches the product and that the lab is named.
  • Impurity limits. Peptides can contain related fragments left from synthesis. A credible product states acceptable limits.
  • Microbial and endotoxin testing. Essential for anything sprayed into the nose or injected.
  • Container and closure. The spray pump and bottle affect dose consistency and contamination risk.

Ingredient-label literacy is a skill that carries across product categories, and resources on reading ingredient safety information cover similar document checks for skincare and supplements. For a worked example of what a real CoA shows, see our explanation of an NAD+ nasal spray certificate of analysis.

Our perspective

We approach every peptide and nasal therapy with the same two questions: what do human studies show, and who is accountable for the product reaching the patient?

For Semax, the honest answer to the first question is that the human record is small, regional and concentrated in stroke. Animal work explains why researchers are interested, but it does not tell a person what a spray will do. We keep those two categories apart on purpose.

The second question is where a licensed model matters. A prescription route means a provider reviews your history, a licensed U.S. pharmacy prepares the medication, and your health information is handled under HIPAA-compliant practices. Our current nasal and injectable offerings, including NAD+ nasal spray and glutathione nasal spray, follow that model, and a Semax page is available for readers who want to see how we describe it.

Decisions about any therapy are individual. A supervising provider, not a product page, is the right place to make them.

Jack

Where to start with a supervised option

Vivo is a telehealth service: intake is online, a licensed provider reviews your information and approves a treatment plan, and prescriptions are compounded by licensed U.S. pharmacies and delivered to your door. That suits busy professionals, frequent travelers and anyone far from a clinic. Treatment selection is guided, and medical supervision continues through refills.

For readers whose interest is in nasal delivery of a longer-studied compound, NAD+ nasal spray is listed at $119 per month and glutathione nasal spray at $149 per month. Browse the full list of plans on the Vivo site.

FAQ

Is Semax nasal spray FDA-approved?

The sources reviewed do not describe it as an FDA-approved drug. In Russia it is sold as a prescription nasal drop. FDA’s 2026 advisory committee review of Semax found insufficient evidence of effectiveness for the uses it examined.

Does Semax improve memory or focus in healthy adults?

Independent academic summaries describe little evidence of a cognitive benefit in healthy people. The human studies that exist are small and mostly involve stroke patients in Russia. A 2024 evidence synthesis rated certainty as very low.

What are the side effects of Semax nasal spray?

FDA found one adverse-event report, involving eye pain and burning after nasal drops bought online, and no published human case reports. Because no human pharmacokinetic studies exist, a typical side-effect profile has not been established. Anyone with a medical condition or who takes medication should speak to their physician first.

Is a research-use-only Semax spray the same as a prescription product?

No. A research-use label signals the product is not made or tested for human use, and FDA noted missing public data on impurities, sterility and endotoxins for Semax. A prescription product involves a licensed provider and a licensed pharmacy.

How do animal studies relate to Semax results in people?

They show mechanisms worth investigating, but cannot confirm effects in humans. Doses used in animals are often higher than those expected in people, and results must be extrapolated across species.

Sources